Metabolic & Fat Loss

HGH Fragment 176-191

Also known as: HGH Frag, Fragment 176-191

Molecular Identifiers

Molecular Formula

C80H127N23O24S2

PubChem CID

172966176

Overview

Synthetic peptide corresponding to amino acids 176-191 of human growth hormone. Promotes lipolysis without effect on insulin or IGF-1.

Sequence (1 letter): FLRIVQCRSVEGSCGF
Extended notation: Phe-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Half-life

~30 minutes

Administration Route

Subcutaneous

Category

Metabolic & Fat Loss

Mechanism of Action

  • Direct lipolysis in adipose tissue
  • No effect on insulin or IGF-1
  • Inhibition of lipogenesis
  • No anabolic activity on muscle tissue

Dosage Protocol

Data compiled from the literature. This does not constitute medical advice.

Parameter Value
Dose 250-500 mcg per injection
Frequency 1-2 times per day
Timing Morning fasted, pre-cardio
Duration 12+ weeks

Reported Side Effects

Adverse effects described in the literature. Severity and frequency vary between individuals.

  • Injection site pain
  • Local redness
  • Mild headache
  • Hypoglycemia (rare)

Presentations & Preparation

Vials of HGH Fragment 176-191 found in the research market:

5 mg10 mg

Reconstitution

  • Diluent: Bacteriostatic water
  • Volume: 2 ml per vial
  • Inject the diluent slowly against the vial wall
  • Gently swirl until fully dissolved
  • Never shake

Storage

  • Lyophilized: Refrigerated 2-8°C
  • Reconstituted: Refrigerated 2-8°C (up to 30 days)
  • Protect from direct light
  • Do not freeze after reconstitution
Reconstitution Calculator

Scientific Studies

Published studies on HGH Fragment 176-191.

2001 · Endocrinology

The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice

Heffernan MA, Jiang WJ, Thorburn AW, Ng FM
2001 · Int J Obes Relat Metab Disord

Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment

Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM

Related Peptides

5-Amino-1MQ

50 mg per capsule · 1-2 times daily

Adipotide

0.5-1 mg/kg per injection (subcutaneous) · Once daily

AICAR

50-150 mg per injection · 2-3 times per week

AOD 9604

300-600 mcg per injection · Once daily

Cagrilintide

1.2-4.5 mg per week (subcutaneous) · Once weekly

Dulaglutide

0.75-4.5 mg per week (subcutaneous) · Once weekly